Patents for A61P 19 - Drugs for skeletal disorders (81,981)
03/2002
03/20/2002CN1081051C Blood stasis removing analgesic plaster and its preparation
03/20/2002CN1081049C Medicine for rheumatic arthritis
03/20/2002CN1081047C Medicinal liquor for treating rheumatism and atrophic arthritis
03/19/2002US6359181 Cyclopentane 1-hydroxy alkyl or alkenyl-2-one or 2-hydroxy derivatives as therapeutic agents
03/19/2002US6359158 A 16-hydroxyeicosatetraenoic acid antagonist; antiinflammatory agents
03/19/2002US6359012 Method for making 24(S)-hydroxyvitamin D2
03/19/2002US6358987 For therapy and prophylaxis of rheumatoid arthritis, osteoarthritis, osteopenias such as osteoporosis, periodontitis, gingivitis, corneal epidermal or gastric ulceration, and tumour metastasis, invasion and growth
03/19/2002US6358980 For therapy of arthritis, tumor metastasis, tissue ulceration, abnormal wound healing, periodontal disease, bone disease, diabetes (insulin resistance) and hiv infection
03/19/2002US6358978 Substituted benzimidazoles
03/19/2002US6358976 For therapy and prophylaxis of cancer metastasis, diabetic retinopathy, neovascular glaucoma, thrombosis, restenosis, osteoporosis, or macular degeneration
03/19/2002US6358970 Integrin receptor antagonists
03/19/2002US6358954 PDGF receptor kinase inhibitory compounds, their preparation, purification and pharmaceutical compositions including same
03/19/2002US6358945 Compounds useful as anti-inflammatory agents
03/19/2002US6358925 Administering insulin-like growth factor
03/19/2002US6358741 Polynucleotide coding propagation regulator; for treating cell proliferative defects
03/19/2002CA2236673C (-)cis-6(s)-phenyl-5(r)-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-5,6,7,8-tetrahydronaphthalen-2-ol d-tartrate
03/18/2002CA2319928A1 Apoptosis-mimicking synthetic entities and use thereof in medical treatments
03/15/2002CA2357155A1 Pharmaceutical composition for preventing or treating a disease associated with an excess of il-12 production
03/14/2002WO2002020822A2 Biopanning and rapid analysis of selective interactive ligands (brasil)
03/14/2002WO2002020813A2 Recombinant endothelial cell growth inhibitors derived from a mammalian plasminogen
03/14/2002WO2002020769A1 Human and mouse targeting peptides identified by phage display
03/14/2002WO2002020762A2 Tnf receptor-like molecules and uses thereof
03/14/2002WO2002020736A2 Proteases
03/14/2002WO2002020724A2 Adenoviral targeting and manipulation of immune system response using targeting peptides
03/14/2002WO2002020723A2 Compositions and methods for targeting peptides in humans in vivo
03/14/2002WO2002020722A2 Methods and compositions for in vitro targeting
03/14/2002WO2002020718A2 Osteoclast-associated receptor
03/14/2002WO2002020619A2 HUMAN ANTIBODIES AGAINST PSEUDOMONAS AERUGINOSA LPS DERIVED FROM TRANSGENIC XENOMOUSE$m(3)
03/14/2002WO2002020615A2 Antibody and/or chemokine constructs which bind to a chemokine receptor and their use in immunological disorders
03/14/2002WO2002020526A2 Cyclic and acyclic amidines and pharmaceutical compositions containing them for use as progesterone receptor binding agents
03/14/2002WO2002020512A1 Imidazolo-5-yl-2-anilino-pyrimidines as agents for the inhibition of the cell proliferation
03/14/2002WO2002020488A2 Quinoline and quinazoline derivatives as ligands for the neuropeptide y receptor
03/14/2002WO2002020485A1 Spiroheterocyclic nitriles useful as reversible inhibitors of cysteine proteases
03/14/2002WO2002020034A1 'pseudo'-native chemical ligation
03/14/2002WO2002020033A1 Polymer-modified synthetic proteins
03/14/2002WO2002020021A1 1alpha-hydroxy-2-methylene-19-nor-homopregnacalciferol and its therapeutic applications
03/14/2002WO2002019994A2 The treatment of inflammatory disorders
03/14/2002WO2002019963A2 Synthetic erythropoiesis stimulating proteins
03/14/2002WO2001090189A3 G-protein coupled receptor org3.
03/14/2002WO2001083713A3 The use of tolerogenic dendritic cells for enhancing tolerogenicity in a host and methods for making the same
03/14/2002WO2001072290A3 Method for the improvement of islet signaling in diabetes mellitus and for its prevention
03/14/2002WO2001070757A3 Thioketals and thioethers for inhibiting the expression of vcam-1
03/14/2002WO2001070734A3 Beta-amino acid derivatives as inhibitors of matrix metalloproteases and tnf-alpha
03/14/2002WO2001070673A3 CYCLIC β-AMINO ACID DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEASES AND TNF-$g(a)
03/14/2002WO2001064046A3 Method for isolating sponge collagen and producing nanoparticulate collagen, and the use thereof
03/14/2002WO2001058852A3 (r)-2-aryl-propionamides, useful in the inhibition of il-8-induced chemiotaxis of neutrophils
03/14/2002WO2001055134A3 Novel 1,3-dihydro-2h-indol-2-one derivatives and their use as ligands for v1b and v1a arginine-vassopressin receptors
03/14/2002WO2001051512A3 Human and parasite orphan receptor proteins
03/14/2002WO2001032130A3 Phenyl amine carboxylic acid compounds and compositions for delivering active agents
03/14/2002WO2001023572A3 Polynucleotides and polypeptides encoded thereby
03/14/2002WO2001020031A3 Polymorphisms in a klotho gene
03/14/2002WO2000074662A3 Arthritis treatment
03/14/2002WO2000065028A9 TGF-α POLYPEPTIDES, FUNCTIONAL FRAGMENTS AND METHODS OF USE THEREFOR
03/14/2002WO2000058483A9 Protozoan expression system
03/14/2002WO2000053742A9 Polynucleotides and proteins encoded thereby
03/14/2002US20020032306 Cyclopeptide derivatives
03/14/2002US20020032224 Treatment of inflammatory diseases and other diseases involving elevated levels of cytokines, as well as central nervous system disorders
03/14/2002US20020032210 Chloride channel blockers; useful in the treatment of sickle cell anaemia, brain edema following iscaemia or tumors, diarrhea, hypertension, bone metabolic disorders, osteoclast associated disoders; substituted biphenyl containing nitrogen
03/14/2002US20020032204 Reacting a substituted indol-2-one compound with an acyclic or cyclic amine free of piperidine-1-yl or morpholine-4-yl to form protein kinase inhibitor
03/14/2002US20020032191 6-phenylpyridyl-2-amine derivatives useful as NOS inhibitors
03/14/2002US20020032181 For therapy of conditions or diseases that are estrogen-dependent, i.e., are estrogen-induced or estrogen-stimulated
03/14/2002US20020031544 Antiinflammatory agents
03/14/2002US20020031496 Therapy for cellular accumulation in chronic inflammatory diseases
03/14/2002DE10041217A1 Verwendung von Dihydroboswelliasäuren oder hydrierten Extrakten aus Boswellia zur prophylaktischen und/oder therapeutischen Behandlung von unerwünschten körperlichen oder seelischen Zuständen Use of Dihydroboswelliasäuren or hydrogenated extracts of Boswellia for prophylactic and / or therapeutic treatment of unwanted physical or mental conditions
03/14/2002DE10023486C1 Ortho substituierte Anthranilsäureamide und deren Verwendung als Arzneimittel Ortho-substituted anthranilic acid amides and their use as medicaments
03/14/2002CA2422204A1 Human antibodies against pseudomonas aeruginosa lps derived from transgenic mice
03/14/2002CA2421922A1 Proteases
03/14/2002CA2421842A1 Antibody and/or chemokine constructs which bind to a chemokine receptor and their use in immunological disorders
03/14/2002CA2421506A1 Cyclic and acyclic amidines and pharmaceutical compositions containing them for use as progesterone receptor binding agents
03/14/2002CA2421380A1 Biopanning and rapid analysis of selective interactive ligands (brasil)
03/14/2002CA2421271A1 Human and mouse targeting peptides identified by phage display
03/14/2002CA2421251A1 Recombinant endothelial cell growth inhibitors derived from a mammalian plasminogen
03/14/2002CA2421200A1 Adenoviral targeting and manipulation of immune system response using targeting peptides
03/14/2002CA2421195A1 Compositions and methods for targeting peptides in humans in vivo
03/14/2002CA2421191A1 Methods and compositions for in vitro targeting
03/14/2002CA2421155A1 Osteoclast-associated receptor
03/14/2002CA2420703A1 Quinoline and quinazoline derivatives as ligands for the neuropeptide y receptor
03/14/2002CA2419601A1 The treatment of inflammatory disorders
03/14/2002CA2417177A1 Spiroheterocyclic nitriles useful as reversible inhibitors of cysteine proteases
03/14/2002CA2412279A1 "pseudo"-native chemical ligation
03/14/2002CA2412278A1 Polymer-modified synthetic proteins
03/14/2002CA2412277A1 Synthetic erythropoiesis stimulating proteins
03/13/2002EP1186617A1 Novel recombinant antibody, amino acid sequences of cdrs thereof and genes encoding the same
03/13/2002EP1186293A2 Intermittent administration of a growth hormone secretagogue
03/13/2002EP1185700A1 49 human secreted proteins
03/13/2002EP1185696A1 Antisense oligonucleotide modulation of human protein kinase c-delta expression
03/13/2002EP1185694A1 49 human secreted proteins
03/13/2002EP1185554A1 Peptide having for fibrinogen fragment e activity, analogs, antibodies and uses thereof
03/13/2002EP1185526A1 Novel quaternary ammonium derivatives, method for preparing same and pharmaceutical use
03/13/2002EP1185524A2 3-heteroarylalkyl substituted gaba analogs
03/13/2002EP1185522A1 Substituted phenyl compounds with immunosuppressing activity and pharmaceutical compositions containing them
03/13/2002EP1185316A1 Devices and compounds for treating arterial restenosis
03/13/2002EP1185296A2 Prevention and treatment of amyloidogenic disease
03/13/2002EP1185285A1 49 human secreted proteins
03/13/2002EP1185284A1 47 human secreted proteins
03/13/2002EP1185271A1 Il-8 receptor antagonists
03/13/2002EP1185270A1 Il-8 receptor antagonists
03/13/2002EP1185265A1 Il-8 receptor antagonists
03/13/2002EP1185261A1 Il-8 receptor antagonists
03/13/2002EP0983249B1 Processes and intermediates for preparing substituted indazole derivatives